Berenberg & Goldman Sachs – 12th German Corporate Conference
Mediathek Category
Mediathek Preview File
Mediathek Download
Mediathek Date
Baader Investment Conference
Mediathek Category
Mediathek Preview File
Mediathek Download
Mediathek Date
- Robert Möller appointed to the Fresenius Management Board; at the same time, Möller will assume responsibility for hospital group as CEO of Helios Health GmbH
- Dr. Francesco De Meo leaves the company
- Management Board team continues to drive forward transformation on the way to #FutureFresenius
The Supervisory Board of Fresenius Management SE has appointed Robert Möller (56) to the Management Board with immediate effect. At the same time, he will take over as Chairman of the Management Board of Helios Health GmbH. He succeeds Dr. Francesco de Meo (59), who will leave the company.
Robert Möller has been CEO of Helios Kliniken GmbH since 2022. He joined Helios in 2014, where he held the position of Clinic Managing Director at Helios Hanseklinikum Stralsund until 2017. After a short time away, he returned to Helios in 2019 and took over the management of various regions. Möller studied human medicine at the University of Hamburg and practiced as a specialist for internal medicine. After various medical positions and a part-time master's degree in health care management, he switched to hospital management while continuing to work as a physician.
"Robert Möller, a physician and proven hospital manager from within the company will now move up to the Management Board. His experience is an excellent addition to the management team. With the further development of the hospital business, he will make an important contribution on the successfully chosen path to #FutureFresenius," said Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius.
"Today, Fresenius is a company with a clear focus and clear responsibilities. We will continue to work together to execute our #FutureFresenius strategy and are well positioned to deliver. Robert Möller addresses the future of healthcare like almost no one else – with a clear focus on digitalization, sustainability and quality. At Helios, he will build on and drive the momentum we have generated so far with #FutureFresenius," said Fresenius CEO Michael Sen.
Helios is Europe's leading private healthcare provider, with approximately 126,000 employees. Together with Quirónsalud in Spain and Latin America and the Eugin Group with a global network of reproductive clinics, Helios Group in Germany is part of the holding Helios Health. With more than 24 million patients per year, the company generated total sales of around 11.7 billion euros in 2022.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch
General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Dr. Sebastian Biedenkopf, Helen Giza, Sara Hennicken, Robert Möller, Dr. Michael Moser
Chairman of the Supervisory Board: Wolfgang Kirsch
Download Image (JPG 687KB)
- Robert Möller appointed to the Fresenius Management Board; at the same time, Möller will assume responsibility for hospital group as CEO of Helios Health GmbH
- Dr. Francesco De Meo leaves the company
- Management Board team continues to drive froward transformation on the way to #FutureFresenius
The Supervisory Board of Fresenius Management SE has appointed Robert Möller (56) to the Management Board with immediate effect. At the same time, he will take over as Chairman of the Management Board of Helios Health GmbH. He succeeds Dr. Francesco de Meo (59), who will leave the company.
Robert Möller has been CEO of Helios Kliniken GmbH since 2022. He joined Helios in 2014, where he held the position of Clinic Managing Director at Helios Hanseklinikum Stralsund until 2017. After a short time away, he returned to Helios in 2019 and took over the management of various regions. Möller studied human medicine at the University of Hamburg and practiced as a specialist for internal medicine. After various medical positions and a part-time master's degree in health care management, he switched to hospital management while continuing to work as a physician.
"Robert Möller, a physician and proven hospital manager from within the company will now move up to the Management Board. His experience is an excellent addition to the management team. With the further development of the hospital business, he will make an important contribution on the successfully chosen path to #FutureFresenius," said Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius.
"Today, Fresenius is a company with a clear focus and clear responsibilities. We will continue to work together to execute our #FutureFresenius strategy and are well positioned to deliver. Robert Möller addresses the future of healthcare like almost no one else – with a clear focus on digitalization, sustainability and quality. At Helios, he will build on and drive the momentum we have generated so far with #FutureFresenius," said Fresenius CEO Michael Sen.
Helios is Europe's leading private healthcare provider, with approximately 126,000 employees. Together with Quirónsalud in Spain and Latin America and the Eugin Group with a global network of reproductive clinics, Helios Group in Germany is part of the holding Helios Health. With more than 24 million patients per year, the company generated total sales of around 11.7 billion euros in 2022.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts.
Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch
General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Dr. Sebastian Biedenkopf, Helen Giza, Sara Hennicken, Robert Möller, Dr. Michael Moser
Chairman of the Supervisory Board: Wolfgang Kirsch
The substance that provides patients with a gentle and safe sleep during anesthesia causes up to 35 percent of all hospital emissions: this is the current reality of anesthetic gas.
Until now, the exhaled gases have been collected from the anesthesia machine and released into the outside air. Anesthetic gases thus promote the greenhouse effect and are among the worst climate killers worldwide. At Fresenius Helios’ 19 hospitals in the eastern region, a new filter system is now being used to recycle these gases. More than 90 percent of the anesthetic gases collected will thus be recycled in the future.
With a consumption of more than 1,200,000 ml of inhalation anesthetics at the 19 clinics in the Helios Region East alone, recycling will save a CO2 equivalent of more than 1,100 tons per year in the future. This is comparable to driving almost five million kilometers in a mid-range gasoline-powered car: more than twelve times from the earth to the moon or 120 times around the equator.
Activated carbon filters are used, which are attached to the anesthesia machine in the operating room or to the ventilator in the intensive care unit – exactly where the exhaust hose for the anesthetic gas is otherwise attached. The gases are captured in these filters and most of them are recycled before they are used again for anesthesia – in line with sustainable recycling management principles. But the filter system not only pays off for the environment. It also reduces costs by eliminating the need for maintenance of the anesthetic gas extraction system. In addition, significant electricity savings can be achieved.
After the trial in the 19 hospitals in the eastern region, Helios will decide whether to implement the project in the other regions in Germany. If all Helios hospitals were to use the new filter system, a CO2 equivalent of around 5,200 tons could be saved in the future. This is equivalent to driving 22,700,000 kilometers with a mid-range gasoline engine. Or put another way, that's 59 times the distance from the earth to the moon.
In addition, Helios has decided to stop using nitrous oxide, which is particularly harmful to the environment. In addition, the emission of the remaining anesthetic gases is reduced as much as possible by intelligently reducing the gas supply to the anesthesia device. For example, the use of desflurane, another very climate-damaging gas, has already been reduced by 40 percent.
According to estimates by the German Society for Anesthesiology and Intensive Care Medicine, 17 million anesthesia procedures are performed in German hospitals each year. Added to this are many thousands more anesthesia procedures in the outpatient sector. Each anesthetic emits up to 118 kilograms of CO2 equivalents.
At Fresenius, we believe we have a responsibility to protect the environment and are striving for climate neutrality by 2040 as part of #FutureFresenius. That’s why we continually implement measures that help reduce our emissions.
Contact
Helios Kliniken GmbH
Friedrichstr. 136
10117 Berlin
Deutschland
T +49 30 521 321-0
The rating agency Fitch today revised the outlook of Fresenius from negative to stable. The rating was affirmed at BBB-. The improved outlook is based on the consistent performance of the Operating Companies, a prudent capital allocation and progress on the group simplification, amongst others. The revised outlook is another strong testament of the successful execution of the strategy towards #FutureFresenius. Fresenius remains committed to its investment grade rating and its self-imposed leverage corridor of 3.0 to 3.5x net debt/EBITDA.
The rating agency Fitch today revised the outlook of Fresenius from negative to stable. The rating was affirmed at BBB-. The improved outlook is based on the consistent performance of the Operating Companies, a prudent capital allocation and progress on the group simplification, amongst others. The revised outlook is another strong testament of the successful execution of the strategy towards #FutureFresenius. Fresenius remains committed to its investment grade rating and its self-imposed leverage corridor of 3.0 to 3.5x net debt/EBITDA.
Goldman Sachs – 20th Annual European Medtech and Healthcare Services Conference
Mediathek Category
Mediathek Preview File
Mediathek Download
Mediathek Date